Latest News from "The Pink Sheet" DAILY - Dendreon Set To Ship Provenge Soon

Dendreon Set To Ship Provenge Within A Week

Demand expected to exceed supply as company builds manufacturing capacity.   read more

 

For BMS, Onglyza Disappoints And Health Care Reform Takes A Toll

The health care reform law, which will lower Bristol-Myers Squibb's sales by $350 million to $400 million this year, led the firm to revise earnings guidance.   read more

 

Sanofi-Aventis' 2010 Guidance Remains Unchanged; Q1 Sales Up 3.9 %

The onset of Lovenox generics could be a near-term reality in the U.S., though timing remains uncertain.   read more

 

Yaz and Betaferon Weigh Down Bayer's Pharma Business, Nexavar Disappoints Too

Recovery in the German conglomerate's materials science division and strong consumer health care sales mask a poor first quarter performance by pharmaceuticals.   read more

 

AstraZeneca's Strong First Quarter Includes Significant Emerging Markets Growth

In China alone, the Big Pharma notes net sales were up 36 percent year over year.   read more

 

U.S. Biosimilars: The "Devil's In The Details," Sandoz Chief Says

Regulatory pathways like 505(b)(2) and BLA, not the new one created through health care legislation, may be best for biosimilars, Sandoz CEO George says.   read more

 

Schwarz Pharma Settles False Claims Suit For $22 Million, As DoJ Continues Focus On DESI Drugs

Lawsuit alleges Schwarz failed to advise CMS that two products, including the nitroglycerin patch Deponit, did not qualify for federal reimbursement.   read more

 

"The Pink Sheet" DAILY - Daily, in-depth analysis of the key developments shaping the biopharma industry. Not a subscriber? To register for a free trial, click here